Shuailiang (Charles) Lin

Dr. Shuailiang (Charles) Lin is one of the pioneers who invented the CRISPR/Cas9 gene editing
system. As named authors and inventors of the original CRISPR/Cas9 paper and patent from Dr.
Feng Zhang's team at the Broad Institute of MIT and Harvard, he has ~15 years’ expertise in
Gene Editing, Gene Delivery and Gene & Cell Therapy.

After his Ph.D. study at the Broad Institute of MIT and Harvard and his postdoctoral fellowship
at UCSF, Dr. Lin established the nanoparticle delivery of CRISPR/Cas9 gene editing platform and
built and led the TCR-T engineering team in Ligandal Inc. His professional leadership further
developed with more responsibilities and roles at Kriya Therapeutics, expanding from leading
therapeutic innovative platforms development to discoveries and translations.

Dr. Lin also serves as advisor and consultant for several VCs and startups.